Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

DOI Web Site 被引用文献3件
  • Michael D. Prados
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Susan M. Chang
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Nicholas Butowski
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Rebecca DeBoer
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Rupa Parvataneni
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Hannah Carliner
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Paul Kabuubi
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Jennifer Ayers-Ringler
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Jane Rabbitt
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Margaretta Page
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Anne Fedoroff
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Penny K. Sneed
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Mitchel S. Berger
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Michael W. McDermott
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Andrew T. Parsa
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Scott Vandenberg
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • C. David James
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Kathleen R. Lamborn
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • David Stokoe
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.
  • Daphne A. Haas-Kogan
    From the University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA.

抄録

<jats:sec><jats:title>Purpose</jats:title><jats:p> This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma. The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma were enrolled. We intended to treat patients not currently treated with enzyme-inducing antiepileptic drugs (EIAEDs) with 100 mg/d of erlotinib during XRT and 150 mg/d after XRT. Patients receiving EIAEDs were to receive 200 mg/d of erlotinib during XRT and 300 mg/d after XRT. After XRT, the erlotinib dose was escalated until patients developed tolerable grade 2 rash or until the maximum allowed dose was reached. All patients received temozolomide during and after XRT. Molecular markers of epidermal growth factor receptor (EGFR), EGFRvIII, phosphatase and tensin homolog (PTEN), and methylation status of the promotor region of the MGMT gene were analyzed from tumor tissue. Survival was compared with outcomes from two historical phase II trials. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Median survival was 19.3 months in the current study and 14.1 months in the combined historical control studies, with a hazard ratio for survival (treated/control) of 0.64 (95% CI, 0.45 to 0.91). Treatment was well tolerated. There was a strong positive correlation between MGMT promotor methylation and survival, as well as an association between MGMT promotor-methylated tumors and PTEN positivity shown by immunohistochemistry with improved survival. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Patients treated with the combination of erlotinib and temozolomide during and following radiotherapy had better survival than historical controls. Additional studies are warranted. </jats:p></jats:sec>

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ